Endpoints News 25. Nov. 2025 Pharma faces deadline to bring IRA fight to Supreme Court as first set of negotiated prices looms
Endpoints News 25. Nov. 2025 FDA OKs Sarepta study of new immune suppression approach with Elevidys; Gilead buys preclinical TREX1 program
Endpoints News 25. Nov. 2025 Novo Nordisk’s amycretin cuts body weight, blood sugar in Phase 2 diabetes trial
Endpoints News 25. Nov. 2025 Novartis was the sole bidder in $12B deal to buy Avidity #Avidity Biosciences #buy Avidity
Endpoints News 24. Nov. 2025 FDA's Pazdur is said to raise questions about commissioners actions, new voucher #commissioners actions #raise questions
Endpoints News 24. Nov. 2025 UK-US drug pricing deal could come as early as this week, sources say #told Endpoints #UK-US drug
Endpoints News 24. Nov. 2025 #ASH25: Kelonia’s first in vivo CAR-T data; Lilly, J&J and Novartis spell out Phase 3 wins #American Society #wins Late-breaking
Endpoints News 24. Nov. 2025 J&J’s tau-targeting antibody fails Phase 2 Alzheimer's study #fails Phase #Alzheimer study
Endpoints News 24. Nov. 2025 Kelun's TROP2 ADC plus Keytruda improves outcomes in first-line lung cancer #first-line lung #lung cancer
Endpoints News 24. Nov. 2025 Sarepta to pay $200M milestone to Arrowhead; Enlivex reports osteoarthritis data #Clearside Biomedical #MindImmune Therapeutics
Endpoints News 24. Nov. 2025 Biogen pens I&I deal with new Versant macrocycle developer Dayra Therapeutics #Versant Ventures’ #Dayra Therapeutics
Endpoints News 24. Nov. 2025 Bayer’s stock rallies as next-gen blood thinner beats the odds with Phase 3 win #win Bayer #high-profile failures
Endpoints News 24. Nov. 2025 Novo Nordisk's semaglutide misses in closely-watched Alzheimer’s trials #Novo Nordisk #closely-watched Alzheimer
Endpoints News 24. Nov. 2025 Craig Crews, Mikael Dolsten raise $32M for Quarry Thera #Mikael Dolsten #Quarry Thera
Endpoints News 24. Nov. 2025 Nobel laureate Carolyn Bertozzi to rejoin Lilly board #Carolyn Bertozzi #Eli Lilly
Endpoints News 22. Nov. 2025 Makary’s user fee comments; M&A activity stays hot; A new use for prime editing; and more #Endpoints Weekly #fee comments
Endpoints News 21. Nov. 2025 Top Makary aide Jain-Nagpal remains at the FDA after White House pushback #White House #Commissioner Marty
Endpoints News 21. Nov. 2025 AstraZeneca to onshore rare disease portfolio as part of its $50B pledge to the US #announced Friday #billion pledge